New Late Breaking Preliminary Data Demonstrate Balt’s Squid™ Liquid Embolic May Improve Outcomes in Patients with Chronic Subdural Hematomas
BOSTON, Feb. 09, 2024 (GLOBE NEWSWIRE) — Balt, Inc., a global technology leader in neurovascular devices, today announced the presentation of preliminary data from The Squid Trial for the Embolization of the Middle meningeal artery (STEM) for the treatment of chronic Sub-Dural Hematoma during the late-breaking session at the International Stroke Conference in Phoenix, AZ. … Read more